$ImmunityBio, Inc.(IBRX)$ When will the EU revenue start rolling in? When does the company reach breakeven and actually start making money? ANKTIVA is a great molecule that still hasn't reached its full potential. It should replace KEYTRUDA, and BioShield should become the cancer vaccine rather than the MRNA approach. This is heading toward a triple-digit stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
